AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: Benralizumab
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05552508
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT05546866
- Locations
- 🇨🇳
Research Site, Tianjin, China
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5480
- Registration Number
- NCT05548777
- Locations
- 🇺🇸
Research Site, Agoura Hills, California, United States
Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT05526690
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Phase 2
Active, not recruiting
- Conditions
- Stage II-IIIB Non-small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 188
- Registration Number
- NCT05526755
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment
Phase 1
Terminated
- Conditions
- Hepatic Impairment
- Interventions
- Combination Product: Cotadutide
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05517226
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Phase 2
Recruiting
- Conditions
- Liver Cirrhosis
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 195
- Registration Number
- NCT05516498
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05514132
- Locations
- 🇨🇳
Research Site, Shandong, China
A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05512806
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT05511025
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath